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Highlights
• Ranked in order of Hazard Ratio (HR), Increasing age (HR 2.31), Smoking (HR 1.79), Ischaemic Heart Disease (IHD) (HR 1.65), Deprivation (HR 
1.36), Hypertension (HR 1.23) and Male gender (HR 1.20) all increased mortality risk (p<0.01).
• This study demonstrated that a man with type 2 diabetes of 5-10 years duration who smoked, had hypertension and IHD plus lived in the most 
deprived area had a HR of 6.2 compared with a non-smoking, normotensive, non-diabetes subject without IHD living in the least deprived area.
• When age was adjusted for in the survival model there was an interaction between hypertension and type 2 diabetes with little increase in 
mortality risk. It is likely that the mechanism(s) underlying type 2 diabetes and hypertension are linked.
• Smoking prevalence decreased with duration falling from 26.8% for diabetes <5 years to 17.7% for diabetes >10 years.
• Body Mass Index >30 kg/m2 appeared to reduce mortality risk (HR 0.77, p<0.01).
• Abnormal lipid levels whilst not on a statin significantly increased mortality risk for raised total-cholesterol (HR 1.74) and low HDL-cholesterol 
(HR 1.48) but not for triglycerides (HR 0.67) (all p<0.01).
Abstract
Background: This study investigated the effects of age, gender, socio-economic status, smoking status, hypertension, ischaemic heart disease, Body 
Mass Index (BMI), Glycaemic control (HbA1c) and dyslipidaemia in type 2 diabetes in a population-based analysis.
Methods: Data were collected from 46 General Practice databases in 2009 and 2014. Cox regressions were run in type 2 diabetes patients plus the 
non-diabetes population.
Results: Individuals with type 2 diabetes (n=16,643) had higher mortality rates than non-diabetes subjects. Ranked in order of Hazard Ratio (HR), 
increasing age (HR 2.31), smoking (HR 1.79), IHD (HR 1.65), deprivation (HR 1.36), hypertension (HR 1.23) and male gender (HR 1.20) all increased 
mortality risk (p<0.01). Statin therapy was associated with better outcome (HR 0.65, p<0.01). Abnormal lipid levels whilst not on a statin significantly 
increased mortality risk for raised total-cholesterol (HR 1.74) and low HDL-cholesterol (HR 1.48) but not for triglycerides (HR 0.67) (all p<0.01).
Conclusions: This large study confirmed that the all-cause mortality risk in type 2 diabetes remains elevated. We demonstrated that a man with 
type 2 diabetes of 5-10 years duration who smoked, had hypertension and IHD plus lived in the most deprived area had a HR of 6.2 compared with 
a non-smoking, normotensive, non-diabetes subject without IHD living in the least deprived area. Further research is required to understand the 
interaction between hypertension and type 2 diabetes plus why obesity and raised triglycerides appeared to be protective in type 2 diabetes.
Keywords: Type 2 diabetes; Age; Gender; Body Mass Index (BMI); Glycaemic control; Socio-economic status; Dyslipidaemia; Hypertension; 
Ischaemic heart disease; Smoking status
Abbreviations: HR: Hazard Ratio; IHD: Ischaemic Heart Disease; BMI: Body Mass Index; HDL cholesterol: High-Density Lipoprotein; SIMD: 
Scottish Index of Multiple Deprivation; SPSS: Statistical Package for the Social Sciences; SD: Standard Deviation; UK: United Kingdom
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Background
Type 2 diabetes is a chronic complex metabolic disease and 
is associated with numerous macrovascular and microvascular 
complications [1]. The management of type 2 diabetes management 
is complex, expensive, involves the management of multiple risk 
factors, requires significant changes in lifestyle behaviors, and regular 
review by health care professionals [2]. The excess in mortality was 
considered to be primarily due to cardiovascular disease although 
we are becoming increasingly aware of the risk of malignancy in type 
2 diabetes [3]. The evidence base for managing type 2 diabetes and 
preventing complications has improved greatly. Glycaemic control 
studies, improved cardiovascular risk factor management and 
smoking cessation have resulted in better outcome data and improved 
care [4-9].
The clinical goal of treatment in people with type 2 diabetes is to 
prevent the onset of associated co-morbidities and reduce the mortality 
risk to a level comparable to non-diabetes individuals. The aims of 
this study were to compare all-cause mortalities in type 2 diabetes 
with a non-diabetes population. We also investigated and ranked the 
effects of age, gender, social deprivation, body mass index (BMI), 
dyslipidaemia, hypertension, ischaemic heart disease and smoking 
status in a population-based analysis in the county of Ayrshire and 
Arran, Scotland over a five-year period.
Methods
Forty six out of fifty-five General Practices in NHS Ayrshire & Arran 
contributed data from their practice computer systems. This covered 
85% of the total patient population (above 18 years) of Ayrshire & 
Arran. Data were provided in 2009 and then again in 2014. There 
was no significant difference in the prevalence of diabetes between 
practices that did and did not provide data (5.5% vs 5.7% χ2=3.3; 
p=0.07).
In a recently published parallel study, we investigated the outcome 
of patients with type 1 diabetes over the same five-year period where 
further information on methodology is available [10]. In both studies, 
survival was measured in days from a ‘start date’ of 1/10/2009 to an 
‘end date’ of 30/09/2014. The number of days between the start and 
end date (survival time) was calculated for each subject. Data on age, 
gender, deprivation [11], smoking status, hypertension and ischaemic 
heart disease, were collected for all subjects. Ischaemic heart disease 
was defined as per the Quality Outcome Framework document 
[12,13]. Data on glycaemic control and lipid levels were only collected 
for those patients with diabetes.
Ethical opinion was not required for this study. The audit was 
registered with the Clinical Governance Department, NHS Ayrshire 
and Arran, UK and Caldicott Guardian approval was obtained from 
each General Practice.
Statistics
Statistical analysis mirrored that of our recent study [10]. A Cox 
regression was run on survival time with type 2 diabetes, gender, 
age (in decades), deprivation (quintile), smoking, hypertension and 
IHD as covariates. Interactions of diabetes groups with all the other 
covariates were also included. Reference group were female, quintile 
1 (least deprived), non-diabetes, non-smoker, normotensive and no 
IHD [10].
BMI data was not included in the initial survival model. Instead a 
matched sample of two non-diabetes subjects for each type 2 diabetes 
subject was selected using propensity score matched on the latest BMI 
reading. After matching there was data on 49371 subjects (66.6% non-
diabetes subjects and 33.3% with type 2 diabetes) and the two groups 
had similar BMI (type 2 diabetes 31.21 ± 6.88 (Mean ± SD) vs non-
diabetes 31.17 ± 6.84, p=0.52). The previous Cox regression was run 
on this subset with BMI >30 k/m2 included as a covariate.
A Cox regression including only patients with type 2 diabetes was 
also run using the same covariates as previously but also included BMI, 
glycaemic control, lipid levels and complications. Baseline categories 
were as above; the baseline for diabetes was duration of less than 5 
years. Statistical analysis was performed using SPSS V21.
Results
In total 269,947 subjects were tracked from 2009 to 2014. 93.8% 
were non-diabetes subjects. 6.2% (16643) had type 2 diabetes. 2.3% 
(6260) had diabetes for less than 5 years, 2% (5353) had diabetes for 
between 5 and 10 years and 1.9% (5030) had diabetes for more than 
10 years. Between 2009 and 2014, 4.5% of the subjects died and 6.5% 
moved from the practices included in the study; the remaining 89.1% 
remained registered. All-cause mortality was 3.9% for non-diabetes 
subjects but was significantly higher for type 2 diabetes. Mortality was 
lowest for duration of diabetes less than 5 years and greatest for those 
with duration 5-10 years (<5 years 10.1%, OR 2.8; 5-10 years 14.7%, 
OR 4.2; >10 years 13.9%, OR 4.0) (Table 1).
Gender and age
There were significantly more males among the patients with type 
2 diabetes (regardless of duration) than non-diabetes subjects (55% 
vs 49%) (χ2=254.7, p<0.01). Non-diabetes subjects were significantly 
younger than type 2 diabetes groups ((Mean ± SD) 45.2 ± 22.2 vs 64.3 
± 13.2 (diabetes <5 years) vs 68.1 ± 12.2 (5-10 years) and 71.1 ± 11.1 
(>10 years), all p<0.01). Females were older than males for all groups 
[mean diff (95% CI) non-diabetes 3.0 years (2.8,3.2); diabetes <5 years 
1.8 years (1.2,2.5); diabetes 5-10 years: 2.0 years (1.4,2.6); diabetes >10 
years: 2.0 years (1.4,2.6): all p<0.01].
Relative mortality of patients with type 2 diabetes compared to 
non-diabetes subjects was similar for both males and females (Table 
1). Once age was taken into account, the survival analysis (Table 2), 
showed that mortality risk was higher for males. There was no gender 
difference or interaction by duration of diabetes. Mortality increased 
with age and was higher for type 2 diabetes across all age groups.
Deprivation and smoking
Deprivation was Health Board weighted [9,12]. For type 2diabetes 
(regardless of duration) there was a clear pattern. Deprivation increased 
from 15.1% in the least deprived quintile to 23.5% in the most deprived 
(Χ2=236.3, p<0.001) (Figure 1). Mortality increased with increasing 
deprivation and was consistently higher for type 2diabetes in each 
quintile (Figure 1). The mortality differential between patients with 
type 2 diabetes and non-diabetes subjects remained similar and in line 
with the overall differential found earlier (Table 1). Both deprivation 
and type 2 diabetes were associated with increased mortality. There 
was, however, no evidence of an interaction effect.
Smoking prevalence at baseline was 22% for non-diabetes subjects. 
For type 2 diabetes prevalence decreased with duration falling from 
26.8% for diabetes <5 years; 21.3% for diabetes 5-10 years to 17.7% 
for diabetes >10 years. Mortality rates were higher for smokers than 
non-smokers, but the differential was smaller among patients with 
type 2 diabetes. Among non-smokers mortality was around four times 
higher for patients with type 2 diabetes (depending on duration) 
while among smokers’ mortality was only around three times higher 
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n=5030 <5 yrs 5-10 yrs >10 yrs
Total 3.9% (9923) 10.1% (632) 14.7% (785) 13.9% (698) 2.8 (2.5,3.0) 4.2 (3.9,4.6) 4.0 (3.6,4.3)
Gender
Female 4.1% (5370) 10.2% (289) 14.6% (353) 14.1% (319) 2.6 (2.3,3.0) 4.0 (3.5,4.5) 3.8 (3.4,4.3)
Male 3.7% (4553) 10.0% (343) 14.7% (432) 13.7% (379) 2.9 (2.6,3.2) 4.5 (4.0,5.0) 4.1 (3.7,4.6)
Age*
<49 0.4% (531) 2.3% (20) 2.0% (8) 3.3% (6) 6.3 (4.0,9.9) 5.4 (2.7,10.9) 9.2 (4.1,20.9)
50-59 1.6% (630) 3.8% (52) 3.8% (34) 3.1% (20) 2.4 (1.8,3.1) 2.3 (1.6,3.3) 1.9 (1.2,3.0)
60-69 4.4% (1436) 7.1% (122) 9.9% (147) 6.5% (82) 1.7 (1.4,2.0) 2.4 (2.0,2.8) 1.5 (1.2,1.9)
70-79 11.1% (2532) 13.6% (203) 18.1% (286) 15.2% (265) 1.3 (1.1,1.5) 1.8 (1.6,2.0) 1.4 (1.3,1.7)
80+ 28.4% (4793) 29.6% (235) 31.7% (310) 27.1% (325) 1.1 NS p=.47 1.2 (1.0,1.30) 0.9 NS p=.35
Deprivation*
Quintile 1 3.7% (1727) 10.5% (94) 13.3% (110) 12.9% (99) 3.1 (2.5,3.8) 4.0 (3.3,4.9) 3.9 (3.1,4.8)
Quintile 2 2.8% (1399) 7.8% (88) 10.9% (104) 9.2% (77) 3.0 (2.4,3.7) 4.3 (3.5,5.3) 3.5 (2.8,4.5)
Quintile 3 4.3% (2157) 11.2% (143) 15.2% (168) 14.2% (154) 2.8 (2.3,3.3) 4.0 (3.3,4.70 3.7 (3.1,4.4)
Quintile 4 4.6% (2376) 11.6% (165) 16.4% (191) 15.8% (185) 2.7 (2.3,3.2) 4.1 (3.5,4.8) 3.9 (3.3,4.6)
Quintile 5 4.1% (2123) 9.0% (134) 15.6% (196) 15.2% (173) 2.3 (1.9,2.8) 4.3 (3.7,5.1) 4.2 (3.6,5.0)
Smoking*
Non smoker 3.7% (7095) 10.1% (461) 14.5% (611) 13.7% (568) 2.9 (2.6,3.2) 4.4 (4.0,4.8) 4.1 (3.7,4.5)
Smoker 5.0% (2687) 10.3% (169) 15.3% (174) 14.6% (130) 2.2 (1.8,2.5) 3.4(2.9,4.0) 3.2 (2.7,3.9)
Hypertension
Normotensive 2.6% (5939) 7.9% (310) 11.9% (280) 12.0% (224) 3.2 (2.8,3.6) 5.0 (4.4,5.6) 5.0 (4.4,5.8)
Throughout 14.0% (3984) 13.7% (322) 16.8% (505) 15.0% (474) 1.0 NS p=.75 1.2 (1.1,1.4) 1.1 NS p=.14
IHD
No 3.1% (7644) 7.8% (415) 11.5% (481) 10.8% (395) 2.6 (2.4,2.9) 4.0 (3.6,4.4) 3.7 (3.3,4.1)
Throughout 23.0% (2279) 22.5% (217) 26.1% (304) 22.3% (303) 1.0 NS p=.71 1.2 (1.0,1.4) 1.0 NS p=.58
Table 1: Mortality by diabetes duration (not adjusted for covariates).
*Missing values: Smoking 13496 (5.0%) Deprivation 2234 (0.9%) Age 25 (0.009%).
Factor Beta ± SE p HR (95% CI)
Type 2 DM compared to non-diabetics 
Diabetes duration <5 yrs 0.22 ± 0.06 <0.01 1.24 (1.11,1.39)
Diabetes duration 5-10 yrs 0.36 ± 0.06 <0.01 1.43 (1.27,1.62)
Diabetes duration >10 yrs 0.19 ± 0.07 <0.01 1.21 (1.06,1.39)
Age (decades) 0.84 ± 0.01 <0.01 2.31 (2.28,2.35)
Gender (Male) 0.18 ± 0.02 <0.01 1.20 (1.15,1.25)
Deprivation compared to Q1
Quintile 2 -0.12 ± 0.03 <0.01 0.89 (0.83,0.95)
Quintile 3 0.20 ± 0.03 <0.01 1.22 (1.15,1.30)
Quintile 4 0.31 ± 0.03 <0.01 1.36 (1.29,1.45)
Quintile 5 0.31 ± 0.03 <0.01 1.36 (1.29,1.45)
Smoker compared to non-smoker 0.58 ± 0.02 <0.01 1.79 (1.71,1.87)
IHD compared to none 0.50 ± 0.02 <0.01 1.65 (1.59,1.75)
Hypertensive compared to normotensive 0.21 ± 0.02 <0.01 1.23 (1.18,1.28)
Diabetes group *Hypertension
Diabetes duration <5 yrs and hypertension -0.07 ± 0.08 0.39 0.93 NS
Diabetes duration 5-10 yrs and hypertension -0.13 ± 0.08 0.10 0.88 NS
Diabetes duration >10 yrs and hypertension -0.24 ± 0.08 <0.01 0.79 (0.67,0.93)
Table 2: Regression coefficients and effect sizes for factors in the cox regression model comparing type 2 diabetes and non-diabetes subjects (adjusted 
for covariates).
Final model Cox and Snell R of 0.10 (p<0.01).
*Missing cases 4.4% A Cox regression that omitted smoking was undertaken with far fewer missing cases (0.9%). This analysis showed no substantial 
changes for all the other covariates.
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Type of patient n % with BMI(≥ 30 kg/m2)
Mortality
Overall BMI (<30 kg/m2) Raised BMI (≥ 30 kg/m2) OR (95%CI) BMI ≥ 30 kg/m
2 vs <30 
kg/m2
Non-diabetes 32907 52.4% (17238) 3.9% (1274) 4.8% (752) 3.0% (522) 0.62 (0.55,0.69) p<0.001
Diabetes duration 
<5 yrs 6150 56.6% (3481) 9.6% (593) 14.3% (382) 6.1% (211) 0.39 (0.32,0.46) p<0.001
Diabetes duration 
5-10 yrs 5324 50.9% (2712) 14.5% (772) 18.9% (494) 10.3% (278) 0.49 (0.42,0.57) p<0.001
Diabetes duration 
>10 yrs 4990 49.3% (2462) 13.7% (685) 17.6% (444) 9.8% (241) 0.51 (0.43,0.60) p<0.001
Total 49371 52.4% (25893) 6.7% (3324) 8.8% (2072) 4.8% (1252) 0.53 (0.49,0.57) p<0.001
Table 3: Mortality by BMI in non-diabetic subjects and type 2 diabetes according to duration (matched file).
Duration of diabetes
<5 yrs (n=6260) 5-10 yrs (n=5353) >10 yrs (n=5030)
Mortality 10.1% (632) 14.7% (795) 13.9% (698)
HbA1c (Mean ± SD) Diff (95% CI) Diff (95% CI) Diff (95% CI)
Survived% (mmol/mol) 7.0 ± 1.3(52.7 ± 14.3)
NS p=0.93
7.3 ± 1.5
(56.2 ± 16.4) 2.64
(1.39,3.89)
7.6 ± 1.6
(60.0 ± 17.5) 3.91
(2.51,5.33)





On statin therapy OR † (95% CI) OR † (95% CI) OR † (95% CI)





(0.44,0.62)Yes 8.8% (369) 13.0% (530) 12.1% (483)
Cholesterol







≥ 5 mmol/l and not on statin therapy 13.3% (106) 24.0% (106) 23.8% (71)
HDL-cholesterol
Male ≥ 1 mmol/l








Female <1.3 mmol/l and not on 
statin therapy
9.7% (102) 18.3% (112) 18.1%(77)
Non-fasting triglycerides






(1.28,2.39)≥ 1.7 mmol/l and not on statin 
therapy 11.9% (96) 20.4% (103) 26.0% (104)
Retinopathy












(1.17,1.88)Yes 17.5% (21) 26.9% (81) 18.6% (95)
Table 4: Mortality in type 2 diabetes by lipids levels and complications (not adjusted for covariates).
Missing values: Triglycerides 361 (2.2%), HDL 387 (2.3%) Cholesterol 75 (0.5%)
1The prevalence of both neuropathy and foot ulcer were low (around 5%) and the overlap between the two conditions was small so the two conditions 
were merged to give more robust estimates.
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Factor Beta ± SE p HR (95% CI)
Type 2 diabetes compared to diabetes duration <5 yrs
Diabetes duration 5-10 yrs 0.16 ± 0.07 0.03 1.17 (1.02,1.36)
Diabetes duration >10 yrs -0.03 ± 0.08 0.72 0.97 NS
Age (decades) 0.58 ± 0.02 <.01 1.79 (1.71,1.88)
Gender (Male) 0.18 ± 0.05 <.01 1.19 (1.08,1.31)
BMI ≥ 30 k/m2 and diabetes duration <5 yrs -0.54 ± 0.09 <.01 0.58 (0.48,0.70)
BMI ≥ 30 k/m2 and diabetes duration 5-10 yrs -0.25 ± 0.08 0.02 0.78 (0.66,0.91)
BMI ≥ 30 k/m2 and diabetes duration >10 yrs -0.22 ± 0.09 <.01 0.81 (0.68,0.95)
Deprivation compared to Q1
Quintile 2 -0.21 ± 0.09 0.02 0.81 (0.68,0.97)
Quintile 3 0.11 ± 0.08 0.15 1.12 NS
Quintile 4 0.26 ± 0.08 <.01 1.30 (1.12,1.51)
Quintile 5 0.21 ± 0.08 <.01 1.23 (1.05,1.43)
Smoker compared to non-smoker 0.32 ± 0.06 <.01 1.38(1.23,1.55)
Hypertensive compared to normotensive 0.16 ± 0.05 <.01 1.17 (1.06,1.29)
IHD compared to none 0.65 ± 0.05 <.01 1.92 (1.74,2.11)
HbA1c 0.02 ± 0.02 0.22 1.02 NS
On statin therapy -0.43 ± 0.07 <.01 0.65 (0.56,0.76)
Raised cholesterol and not on statin therapy 0.56 ± 0.09 <.01 1.74 (1.47,2.06)
Low HDL-cholesterol and not on statin therapy 0.39 ± 0.09 <.01 1.48 (1.24,1.75)
Raised triglycerides and not on statin therapy -0.40 ± 0.09 <.01 0.67 (0.56,0.80)
Retinopathy -0.36 ± 0.05 <.01 0.70 (0.63,0.77)
Ulcer/Neuropathy 0.43 ± 0.08 <.01 1.53 (1.31,1.79)
Table 5: Regression coefficients and effect sizes for factors in the cox regression model of type 2 diabetes (adjusted for covariates).
Final model Cox and Snell R of 0.12 (p<0.01).
for patients with type 2 diabetes. Once other factors were considered 
there was no evidence of an interaction between smoking and type 2 
diabetes as confirmed by the survival analysis (Table 2).
Hypertension and Ischaemic Heart Disease (IHD)
The prevalence of hypertension at baseline was 11.2% for non-
diabetes. For type 2 diabetes, the prevalence of hypertension increased 
with duration rising from 37.4% for diabetes duration <5 years; 56.0% 
for diabetes duration 5-10 years to 63.0% for diabetes duration >10 
years (p<0.01). Mortality rates were higher for hypertensive patients 
compared with normotensive patients, but the differential was smaller 
among patients with type 2 diabetes. In individuals with hypertension, 
mortality was similar for both non-diabetes individuals and patients 
with type 2 diabetes (Table 1). Once other factors were considered 
there was still evidence of an interaction between hypertension and 
type 2 diabetes as confirmed by the survival analysis (Table 2). This 
suggests that the increase in mortality risk from a combination of type 
2 diabetes and hypertension was not simply additive.
The prevalence of IHD at baseline was 3.9% for non-diabetes 
subjects. For type 2 diabetes the prevalence increased with duration 
rising from 15.4% for diabetes duration <5 years; 21.7% for diabetes 
duration 5-10 years to 27.0% for diabetes duration >10 years (p<0.01). 
Mortality rates were higher for IHD than non-IHD patients, but the 
differential was smaller among patients with type 2 diabetes. Among 
patients with no history of IHD, mortality risk was around three to 
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four times higher for type 2 diabetes (depending on duration). Among 
IHD patients, however, mortality was similar for both non-diabetes 
subjects and type 2 diabetes patients (Table 1).Once other factors, 
particularly age, were considered there was no evidence of an 
interaction between IHD and type 2 diabetes as confirmed by the 
survival analysis (Table 2).
Survival analysis
The Cox regression model which compared patients with type 2 
diabetes and non-diabetes subjects included 95.6% of cases. 12,003 
(4.4%) of the whole cohort were excluded mostly due to lack of smoking 
data. There were 11,717 (4.3%) deaths among the included cases. The 
effect size (HR) and significance (p) for the variables in the model are 
available in table 2. Only significant interactions are included.
When all other factors were considered, patients with type 2 
diabetes had higher mortality risk than non-diabetes individuals. 
Increasing age, deprivation, being male, smoking, hypertension and 
IHD all increased mortality risk. Apart from hypertension, there were 
no significant interaction effects with type 2 diabetes. Patients with 
type 2 diabetes and hypertension had a lower mortality risk than 
would be expected from the individual risk factors although this was 
only statistically significant for those with diabetes for over 10 years 
(Table 1).
Body mass index (matched sample)
In the smaller matched sample, 52.4% of non-diabetes subjects 
and 52.6% of type 2 diabetes had a BMI at >30 kg/m2 (p=0.70). The 
prevalence of BMI at >30 kg/m2 decreased with duration of diabetes 
falling from 56.6% for <5 years to 49.3% for >10 years (Table 3).
Mortality was significantly lower for those with BMI >30 kg/m2 
for all groups (Table 3). However, those with BMI >30 kg/m2 were 
significantly younger than those with lower BMI in all type 2 diabetes 
groups (<5 years: 60.9 ± 12.6 vs 68.5 ± 12.4; 5-10 years 64.5 ± 11.6 vs 
71.8 ± 11.8; >10 years: 67.9 ± 10.5 vs 74.1 ± 10.8; all p<.001) and this 
will have exaggerated the difference in mortality rates.
A similar survival model was undertaken on the matched file with 
the addition of BMI as a covariate. The Hazard Ratio (HR) for BMI 
>30 kg/m2 was 0.77 (95% CI: 0.71,0.83) indicating that those with 
BMI >30 kg/m2 had a lower mortality risk once other covariates were 
considered. There was no significant interaction between diabetes and 
BMI and there were no substantive differences on any of the other 
covariates included in the previous model.
Glycaemic control and lipid levels (type 2 diabetes patients 
only)
HbA1c and lipids were only routinely measured in subjects with 
type 2 diabetes. The latest reading was used in the analysis. There was 
no significant difference in mean HbA1c between those who survived 
and those who died when diabetes duration was less than 5 years. For 
subjects with diabetes duration of over 5 years, those who survived 
had a slightly but significantly higher mean HbA1c (Table 4).
7.5% (1249) had no defined lipids abnormality and were not on 
statin therapy. 73.9% (12293) were on statin therapy. The prevalence 
of statin therapy increased by duration of diabetes (<5 years 67.2%; 
5-10 years 76.3%; >10 years 79.5%; p<0.01). 18.6% (3101) had at least 
one defined lipid abnormality and were not on statin therapy. The 
prevalence a lipid abnormality decreased with duration of diabetes 
(<5 years 23.9%; 5-10 years 17.1%; >10 years 13.6%; p<0.01). This is 
consistent with a lipid abnormality being associated with increasing 
mortality.
9.3% (1538) had a total-cholesterol >5 mmol/L but were not on 
statin therapy; 10.5% (1714) had a low HDL-cholesterol but were not 
on statin therapy. 12.9% (2095) had non-fasting triglycerides >1.7 
mmol/L and were not statin therapy. In all cases prevalence of these 
abnormalities decreased with duration (total-cholesterol 12.9%; 8.2%; 
5.9%: HDL-cholesterol 13.3%; 9.6%; 8.1%: non-fasting triglycerides 
17.3%; 11.7%; 8.6%: all p<0.01) which is again consistent with 
increasing mortality.
Those on statin therapy had significantly lower mortality risk 
regardless of duration of diabetes. Those not on statin therapy 
and with a raised cholesterol and low HDL-cholesterol had higher 
mortality than those with normal levels. Probably due to the relatively 
small numbers, the difference was only significant for those with 5-10 
years diabetes duration (increased total-cholesterol) and over 10 years 
duration (reduced HDL-cholesterol). For non-fasting triglycerides, 
mortality was lower for those with levels >1.7 mmol/L but was only 
significant for those with diabetes duration of less than 5 years 
(Table 4).
Diabetes complications
The prevalence of retinopathy was 53.2% while the prevalence of 
neuropathy/foot ulcer was 5.6%. As expected, the prevalence of both 
increased with duration of diabetes (retinopathy 36.0%; 57.0%; 70.7%: 
neuropathy/foot ulcer 1.9%; 5.6%; 10.2%: all p 0.01). Mortality was 
significantly higher for those with neuropathy/foot ulcer regardless of 
duration of diabetes (Table 4). Mortality was significantly lower for 
those with retinopathy regardless of duration of diabetes. This may 
be related to the use of statin therapy and hypertensive medication. 
Both of these class of medications had a significantly higher uptake 
in those with retinopathy (statin therapy: 78% vs 69% (OR=1.55) and 
anti-hypertensive medication: 55% vs 47% (OR=1.40)).
Survival analysis (type 2 diabetes only)
In the Cox regression model including only type 2 diabetes there 
were 15852 patients. Mostly due to missing lipid level data, 792 (4.8%) 
were excluded. There were 1856 (11.2%) deaths among the included 
cases. Table 5 gives the effect size (HR) and the significance (p) for the 
variables in the final model. Only significant interactions are included.
As with the previous model, increasing age, being male, deprivation, 
smoking, and IHD all increased mortality risk. Duration of diabetes 
5-10 years also increased mortality risk. Mortality risk was not 
increased with the longer duration >10 years. Hypertension now 
significantly affected mortality risk although the effect size was small. 
This confirmed the results in table 1 where there was a small increase 
in mortality for hypertensive type 2 diabetes patients compared with 
normotensive type 2 diabetes patients.
Being on statin therapy had a beneficial effect. Abnormal lipid levels 
whilst not on a statin significantly increased mortality risk for raised 
cholesterol and low HDL-cholesterol but not for triglycerides. Patients 
with foot ulcer/neuropathy had increased mortality risk but patients 
with retinopathy had reduced mortality risk (Table 5).
There were no significant interactions with duration of type 2 
diabetes except for BMI at risk. Those with diabetes <5 years and BMI 
>30 kg/m2 had a lower mortality risk than those with diabetes duration 
of >5 years. This is in line with the results in table 3. Age corrected in 
this model had HR for BMI >30Kg/m2 at 0.58 for type 2diabetes <5 
years; at 0.78 for diabetes 5-10 years and 0.81 for diabetes >10 years.
Discussion
The present “real world” study confirmed that patients with 
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type 2 diabetes still have an increased mortality risk [3]. This large 
observational study had an accurate data base and is much larger than 
previous studies. Although some of the findings are not new, they are 
consistent with previous work and the size of the study allows us to 
rank the importance of the different risk factors. Increased mortality 
risk in type 2 diabetes was associated with being male while we 
previously demonstrated that the increased mortality risk in type 1 
diabetes was associated with women [10]. Increased mortality was 
also associated with social deprivation, smoking, ischaemic heart 
disease and hypertension but not glycaemic control. Obesity and 
statin therapy appeared to be associated with reduced mortality risk. 
The present study showed that a male type 2 diabetes subject of 5-10 
years duration who smoked, had hypertension and IHD plus lived in 
the most deprived area had a HR of 6.2 compared with a non-smoking, 
normotensive, non-diabetes subject without IHD living in the least 
deprived area.
The effect of duration on mortality risk in type 2 diabetes was 
interesting. The HRs for type 2 diabetes with duration less than 5 years 
and for 5-10 years were increased but fell slightly with duration greater 
than 10 years. This would appear to reflect selection bias among those 
with longer diabetes duration. These patients will have had diabetes 
for varying periods prior to the study and so there will have been 
mortalities in this group prior to the study period. Mortality risk 
among this “healthier” group of patients’ will have underestimated the 
impact of duration and is an issue in any cross-sectional cohort study.
Social deprivation, measured by SIMD, which provides an area-
based measure of deprivation, has previously been shown to be 
associated with type 2 diabetes and poorer outcome [14,15]. Although 
SIMD data zone may underestimate socioeconomic disparities, it is 
a relatively robust measure compared with previous indices used to 
measure social deprivation [11]. Debate continues as to the why social 
deprivation-related health inequalities are observed in many disease 
processes and populations [14,16]. In our study there was, however, no 
interaction seen between type 2 diabetes and social deprivation [14].
Numerous studies have demonstrated that good glycaemic control 
improves microvascular outcomes [3-6]. The relationship between 
good glycaemic control in type 2 diabetes and improvement in 
outcome has been more difficult to demonstrate [5,6]. Our study did 
not demonstrate better outcome in people with type 2 with a lower 
mean HbA1c. It may be that at this level of mean glycaemic control, 
differences in outcome are difficult to demonstrate and that five 
years is too short a period to demonstrate improvement in outcome. 
Furthermore, those patients with diabetes related or unrelated end 
stage disease may have had a lower HbA1c which would have skewed 
the results. It is also relevant to mention that The American BRAVO 
risk engine published in 2018 found a glycosylated haemoglobin 
level of 7.12%, which was very close to the mean HbA1c in our 
study, was associated with the lowest risk for all-cause mortality in 
type 2 diabetes [17].
The prevalence of obesity in the type 2 diabetes patients in this study 
was greater than in the background population [15]. The presence of 
obesity appeared to protect against mortality risk in people with type 
2 diabetes. With duration of diabetes, the presence of obesity in type 
2 diabetes increased the mortality risk but the HR but still appeared 
protective. Previously, this effect has been described as the “Obesity 
Paradox” and has been demonstrated in type 1 diabetes [10], patients 
with coronary heart disease undergoing percutaneous coronary 
intervention, patients with hypertension, coronary heart disease 
and chronic heart failure [18-22]. Numerous mechanisms have been 
suggested and discussed elsewhere in detail [10,18-22].
Both hypertension and IHD were more prevalent in type 2 diabetes 
and became more prevalent with increased duration of diabetes. The 
mortality risk for hypertension and IHD was significantly higher for 
both normal and type diabetes subjects. When age was adjusted for 
in the survival model there was an interaction between hypertension 
and type 2 diabetes with little increase in mortality risk. This does 
not suggest that having hypertension is a positive factor for type 2 
diabetes. It demonstrates that in type 2 diabetes, hypertension does 
not further increase your mortality risk significantly. It is likely that the 
mechanism(s) underlying hypertension and type 2 diabetes are similar 
[23,24]. In addition, hypertension may be better managed among 
type 2 patients with greater use of cardio-protective antihypertensive 
medications such as angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers [25]. Furthermore, it is likely that 
hypertensive type 2 patients are more likely to be taking statin therapy 
than their non-diabetes counterparts [24].
This study also confirmed that those type 2 patients on statin therapy 
had a significantly lower mortality risk [26,27]. Patients not on statin 
therapy and with a raised total cholesterol or low HDL-cholesterol had 
a higher mortality risk than those with normal levels. For non-fasting 
triglycerides, mortality was lower for those with levels >1.7 mmol/L. 
An inverse association or lack of any association between triglycerides 
levels and outcome has been reported before [28]. Low triglyceride 
levels may result from malnourishment and weight loss related to 
chronic illness and the explanation may also be linked to the “Obesity 
Paradox” already discussed.
The relatively high level of statin therapy and treatment of 
hypertension probably reflects the QOF-driven [29] general 
improvement in diabetes care in Scotland and the UK. The 
management of type 2 diabetes is guideline-driven [30] and as a result 
management is very similar Scotland and UK-wide. This study also 
demonstrates that a significant portion of type 2 diabetes patients 
are not on appropriate anti-hypertensive and statin therapy leaving 
significant room for improvement [31]. We believe that our results are 
generalisable nationally.
Conclusion
This study confirmed that the all-cause mortality risk in people 
with type 2 diabetes remains elevated. In excess of 98% of our subjects 
were Caucasian so further work is required in other ethnic groups. 
Further work is also required to understand the interaction between 
hypertension and type 2 diabetes, why some patients of longer duration 
appear to be “protected”, the role of the “Obesity Paradox” and why 
raised non-fasting triglycerides appears to reduce mortality risk.
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